Monograph Details
|
|
Neoplasms
> Topoisomerase inhibitors
|
|
ETOPOPHOS |
| Manufacturer |
|
Bristol-Myers Squibb |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Topoisomerase inhibitor. |
| Generic Name |
|
Etoposide (as phosphate) 100mg/vial; pwd for IV infusion after reconstitution and dilution. |
| Indications |
|
Refractory testicular tumors after appropriate radiation, surgery, and other chemotherapy. Small cell lung cancer. |
| Children |
|
Not recommended. |
| Adults |
|
See literature. Give by IV infusion over 5 to 210 minutes; use doses equivalent to those used for VePesid (eg, for testicular cancer: range 50–100mg/m2 per day on days 1 through 5 to 100mg/m2 per day on days 1, 3, 5. For small cell lung cancer: range 35mg/m2 per day for 4 days to 50mg/m2 per day for 5 days). Repeat course every 3 to 4 weeks after recovery (esp myelosuppression). Toxicity unknown at doses >175mg/m2 per day. Renal impairment (CrCl ≤50mL/min): reduce dose (see literature). Consider dose reduction with existing myelosuppression due to previous radiation or chemotherapy. |
| Precautions |
|
Monitor blood (esp. CBCs/differential, platelets, hemoglobin) before each cycle and during therapy; renal function. Withhold dose if platelet count <50,000/mm3 or ANC <500/mm3. Hypoalbuminemia. Elderly. Pregnancy (Cat.D); nursing mothers: not recommended. |
| Interactions |
|
Caution with levamisole, others that inhibit phosphatase activity. May be potentiated by cyclosporine. Additive toxicity with radiation, other cytotoxic therapies. |
| Adverse Reactions |
|
Hypersensitivity/infusion reactions (eg, fever/chills, hypotension, bronchospasm), GI upset, mucositis, myelosuppression (esp. neutropenia, thrombocytopenia; may be fatal), asthenia, alopecia, fever, infections, peripheral neurotoxicity; rare: acute leukemia; others. |
| How Supplied |
|
Single-dose vials—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
